ENZY Stock Overview
A life science company, develops and sells products that treat and alleviate infections and symptoms in the upper respiratory tract.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Enzymatica AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | SEK 1.87 |
52 Week High | SEK 4.43 |
52 Week Low | SEK 1.84 |
Beta | -0.0091 |
11 Month Change | -24.60% |
3 Month Change | -39.48% |
1 Year Change | -34.15% |
33 Year Change | -82.02% |
5 Year Change | -56.41% |
Change since IPO | -74.73% |
Recent News & Updates
Recent updates
Shareholder Returns
ENZY | SE Pharmaceuticals | SE Market | |
---|---|---|---|
7D | -3.6% | -2.4% | -4.3% |
1Y | -34.2% | 74.8% | 12.6% |
Return vs Industry: ENZY underperformed the Swedish Pharmaceuticals industry which returned 73% over the past year.
Return vs Market: ENZY underperformed the Swedish Market which returned 12.5% over the past year.
Price Volatility
ENZY volatility | |
---|---|
ENZY Average Weekly Movement | 11.7% |
Pharmaceuticals Industry Average Movement | 10.8% |
Market Average Movement | 5.8% |
10% most volatile stocks in SE Market | 12.2% |
10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: ENZY's share price has been volatile over the past 3 months.
Volatility Over Time: ENZY's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2007 | 16 | Claus Egstrand | www.enzymatica.se |
Enzymatica AB (publ), a life science company, develops and sells products that treat and alleviate infections and symptoms in the upper respiratory tract. The company’s product includes ColdZyme, a mouth spray to treat and alleviate cold and flu symptoms. It also provides enzyme formulations for skin care.
Enzymatica AB (publ) Fundamentals Summary
ENZY fundamental statistics | |
---|---|
Market cap | SEK 324.22m |
Earnings (TTM) | -SEK 55.95m |
Revenue (TTM) | SEK 44.95m |
7.2x
P/S Ratio-5.8x
P/E RatioIs ENZY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ENZY income statement (TTM) | |
---|---|
Revenue | SEK 44.95m |
Cost of Revenue | SEK 16.19m |
Gross Profit | SEK 28.76m |
Other Expenses | SEK 84.72m |
Earnings | -SEK 55.95m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 07, 2024
Earnings per share (EPS) | -0.32 |
Gross Margin | 63.99% |
Net Profit Margin | -124.47% |
Debt/Equity Ratio | 38.7% |
How did ENZY perform over the long term?
See historical performance and comparison